[A case report of metastatic anal fistula cancer treated with neoadjuvant chemotherapy].

A 69-year-old man with perianal pain was diagnosed with an anal fistula and a rectal tumor by magnetic resonance imaging and pulmonary tuberculosis by computed tomography. A colonoscopy confirmed the presence of a circular mass in the rectum 6 cm from the anal verge. Histological examination revealed a moderately differentiated adenocarcinoma.

[Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].

We examined the clinical results of 15 patients treated with imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumors(GIST)at the Osaka City General Hospital. Treatment with imatinib was initiated at 400 mg daily; however, in case of severe adverse events, the dose was gradually reduced to 300 mg or 200 mg to reach a tolerable dose so that administration could be continued for as long as possible. Assessments were performed according to the Response Evaluation Criteria in Solid Tumors(RECIST)and Choi criteria.

[Two long-term survival cases of unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy and radiation therapy].

The prognosis for patients with unresectable intrahepatic cholangiocarcinoma(ICC) is extremely poor. Case 1 was a 65- year-old woman who had an ICC of 9 cm in diameter (mass-forming type) in the right lobe with portal trunk invasion. She was treated with hepatic arterial infusion chemotherapy[cisplatin(CDDP)/5-fluorouracil(5-FU)/l-leucovorin(l-LV)] and radiation therapy (total dose, 50 Gy).

[A case of recurrent gastrointestinal stromal tumor with complete response from treatment with reduced dose of imatinib mesylate].

We report a patient who had a complete response by treatment with 200 mg of imatinib mesylate daily for peritoneal recurrences of gastrointestinal stromal tumor(GIST)of the stomach. On March 2007, a 68-year-old woman underwent distal gastrectomy for GIST of the stomach. On May 2007, peritoneal recurrences were recognized on CT scan, and treatment with 400 mg daily of imatinib mesylate was started.

Cervical impalement injury to a child by a chopstick diagnosed with computed tomography and ultrasonography.

Injuries penetrating into the floor of the mouth in the oral cavity caused by chopsticks are rare. We report a case of neck impalement injury caused by a wooden chopstick fragment penetrating all the way through the base of the tongue. An 18-month-old boy fell off his chair when he was biting on a wooden chopstick.

[Two cases of advanced gastric cancer completely responding to S-1 neoadjuvant chemotherapy].

CASE 1: A 67-year-old man had advanced gastric cancer with lymph node metastasis (cT3N1M0, cStage IIIA). S-1 120 mg was administered for 21 days as neoadjuvant chemotherapy (NAC). A month later, total gastrectomy (with splenectomy) was performed.

A role for elastography in the diagnosis of breast lesions by measuring the maximum fat lesion ratio (max-FLR) by tissue Doppler imaging.

Background: The role of elastography for breast tumors is still ambiguous. The purpose of this study was to inquire how effectively elastography can be used in the diagnosis of breast tumors.

Methods: The fat lesion ratio (FLR) of 244 lesions (99 malignant and 145 benign lesions) was calculated using tissue Doppler imaging with elastography.

[Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].

Eight patients with inoperable advanced gastric cancer were treated with combination chemotherapy of S-1, low-dose cisplatin(CDDP)and Lentinan. S-1 80 mg/ m² was orally administered for 2 weeks followed by 1-week rest, CDDP 15 mg/ m² and Lentinan 2 mg/body were given intravenously on day 1 and 8. One complete response and four partial responses were observed for an overall response rate of 63%(5 of 8 patients).

[Introduction and management of a liaison-clinical pathway for patients with gastric cancer after curative operation].

A liaison-clinical pathway for patients with stageI to III gastric cancer after curative operation has been introduced and managed in our hospital from July 2009. We made two kinds of liaison-clinical pathway in the presence or absence of postoperative adjuvant therapy. The duration of follow-up was 5 years in proportion to the Guidelines for Diagnosis and Treatment of Carcinoma of the Stomach.

[A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks].

We reported a patient with advanced gastric cancer successfully treated with S-1 chemotherapy for three weeks. The patient was a 67-year-old man who had gastric cancer clinically diagnosed as cT3N1H0P0M0, stage IIIA. His treatment was supposed to be daily oral administration of 120 mg S-1 for 28 days.

[A case of the local advanced gastric cancer which became a resection possible in S-1/CDDP/lentinan neoadjuvant chemotherapy].

A 61-year-old man with esophagus invasive advanced gastric cancer and peritoneum dissemination underwent three courses of S-1/CDDP/Lentinan (LNT) combination neoadjuvant chemotherapies (T3N1P1H0, Stage IV) (It is S-1 80 mg/m2,CDDP 15 mg/m2 and LNT 2 mg/body twice/week for two weeks) since down staging was obtained. We performed the surgery of total gastrectomy, splenectomy, D2 lymph node dissection, and Roux-en Y reconstruction in March 2008. With the surgical examination, there was no ascites and peritoneal dissemination.